These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29179281)

  • 21. Evaluation of Weighted Diffusion Subtraction for Detection of Clinically Significant Prostate Cancer.
    Sato T; Isoda H; Fujimoto K; Furuta A; Fujimoto M; Ito K; Kobayashi T; Nakamoto Y
    J Magn Reson Imaging; 2021 Dec; 54(6):1979-1988. PubMed ID: 34085328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal high b-value for diffusion weighted MRI in diagnosing high risk prostate cancers in the peripheral zone.
    Agarwal HK; Mertan FV; Sankineni S; Bernardo M; Senegas J; Keupp J; Daar D; Merino M; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2017 Jan; 45(1):125-131. PubMed ID: 27383502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging Facilities' Adherence to PI-RADS v2 Minimum Technical Standards for the Performance of Prostate MRI.
    Esses SJ; Taneja SS; Rosenkrantz AB
    Acad Radiol; 2018 Feb; 25(2):188-195. PubMed ID: 29107458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.
    Hassanzadeh E; Glazer DI; Dunne RM; Fennessy FM; Harisinghani MG; Tempany CM
    Abdom Radiol (NY); 2017 Jan; 42(1):278-289. PubMed ID: 27522352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
    Yim JH; Kim CK; Kim JH
    J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience.
    Di Campli E; Delli Pizzi A; Seccia B; Cianci R; d'Annibale M; Colasante A; Cinalli S; Castellan P; Navarra R; Iantorno R; Gabrielli D; Buffone A; Caulo M; Basilico R
    Eur J Radiol; 2018 Apr; 101():17-23. PubMed ID: 29571792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of computed diffusion-weighted MRI for predicting aggressiveness of prostate cancer.
    Waseda Y; Yoshida S; Takahara T; Kwee TC; Matsuoka Y; Saito K; Kihara K; Fujii Y
    J Magn Reson Imaging; 2017 Aug; 46(2):490-496. PubMed ID: 28152258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
    Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
    Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DWI of the prostate: Comparison of a faster diagonal acquisition to standard three-scan trace acquisition.
    Corcuera-Solano I; Wagner M; Hectors S; Lewis S; Titelbaum N; Stemmer A; Rastinehad A; Tewari A; Taouli B
    J Magn Reson Imaging; 2017 Dec; 46(6):1767-1775. PubMed ID: 28301097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience.
    Byun J; Park KJ; Kim MH; Kim JK
    J Magn Reson Imaging; 2020 Aug; 52(2):577-586. PubMed ID: 32045072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
    Roh AT; Fan RE; Sonn GA; Vasanawala SS; Ghanouni P; Loening AM
    Curr Probl Diagn Radiol; 2020; 49(3):173-176. PubMed ID: 31126664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml.
    Wang X; Wang JY; Li CM; Zhang YQ; Wang JL; Wan B; Zhang W; Chen M; Li SY; Wan G; Liu M
    Chin Med J (Engl); 2016 Jun; 129(12):1432-8. PubMed ID: 27270538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer.
    Rudolph MM; Baur ADJ; Cash H; Haas M; Mahjoub S; Hartenstein A; Hamm CA; Beetz NL; Konietschke F; Hamm B; Asbach P; Penzkofer T
    Sci Rep; 2020 Sep; 10(1):15982. PubMed ID: 32994502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
    Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
    Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer.
    Park SY; Shin SJ; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ; Oh YT
    Eur Radiol; 2017 Jul; 27(7):2776-2783. PubMed ID: 27957637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Computed Diffusion-Weighted Imaging b2000 and Acquired Diffusion-Weighted Imaging b2000 for Detection of Prostate Cancer.
    Kim YJ; Kim SH; Baek TW; Park H; Lim YJ; Jung HK; Kim JY
    J Korean Soc Radiol; 2022 Sep; 83(5):1059-1070. PubMed ID: 36276208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiparametric MRI of the prostate: diagnostic performance and interreader agreement of two scoring systems.
    Lin WC; Muglia VF; Silva GE; Chodraui Filho S; Reis RB; Westphalen AC
    Br J Radiol; 2016 Jun; 89(1062):20151056. PubMed ID: 27007818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.
    Lim CS; Abreu-Gomez J; Flood TA; Carrion I; Dallaire FB; Schieda N
    Eur Radiol; 2021 Oct; 31(10):7792-7801. PubMed ID: 33782767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T.
    Rosenkrantz AB; Kim S; Campbell N; Gaing B; Deng FM; Taneja SS
    AJR Am J Roentgenol; 2015 Mar; 204(3):W266-72. PubMed ID: 25714311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.